PDCD1 and neoplasm: PD-1-cis-targeted IL-2Rβγ agonists1. Bound to PD-1 and IL-2Rβγ;2. In vivo;3. Suppressed tumor growth;4. Expanded CD8+ TILs with better effector function;5. Decreased the expression of exhaustion-related genes such as Havcr2, Tigit and Tox in CD8+ TILs;6. Increased expression of genes involved in productive and protective immune memory in CD8+ TILs;